TYRA
Tyra Biosciences Inc
20.20$
-3.3%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Cash Flow
Tyra Biosciences Inc (TYRA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -31 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.5 | -1.6 | -2.1 | -2.5 | -4.7 | -4.5 | -5.6 | -9.0 | -8.9 | -17 | -12 | -12 | -9.8 | -9.6 | -17 | -14 | -22 | -10 | -18 | -20 | -25 | -24 | -22 | -24 | -33 | -31 | -110 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.5 | |
| 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.3 | 0.5 | 1.9 | 4.0 | 2.7 | 1.0 | 2.9 | 2.4 | 2.5 | 4.4 | 4.2 | 4.1 | 4.4 | 7.6 | 6.7 | 6.4 | 6.4 | 7.6 | 7.6 | 7.8 | 10 | 33 | |
| – | – | 0.1 | 0.1 | 0.2 | 0.3 | 0.5 | 1.9 | 4.0 | 2.7 | 1.0 | 2.9 | 2.4 | 2.5 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.1 | -0.1 | 0.1 | 1.0 | -0.7 | 0.7 | 0.5 | -1.0 | 1.9 | -4.8 | -0.8 | -2.1 | 1.5 | -0.6 | -5.1 | 6.3 | -6.8 | 5.8 | 0.0 | 0.3 | -3.0 | -1.4 | 0.2 | 2.6 | -1.2 | 4.3 | 5.8 | |
| 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.3 | 0.1 | 0.2 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.6 | 0.1 | 0.5 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.3 | |
| -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.2 | -0.2 | -0.1 | -0.2 | -0.3 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | -144 | 18 | -145 | 22 | 7.0 | 32 | 21 | -15 | 34 | -120 | 18 | -83 | |
| – | – | – | – | – | – | 0.0 | – | – | – | – | – | 0.0 | 0.0 | 0.0 | – | -0.2 | -0.3 | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | |
| – | – | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 23 | 0.1 | 0.0 | 0.0 | 130 | -0.7 | 183 | -1.5 | 0.2 | 0.0 | 0.4 | 0.0 | 0.4 | 0.4 | 0.5 | 0.3 | 200 | 0.4 | 0.7 | 0.7 | 2.2 | 0.6 | 0.6 | 4.7 | 160 | 2.1 | 168 | |
| 22 | -1.6 | -2.2 | -2.6 | 125 | -5.4 | 178 | -11 | -8.9 | -17 | -12 | -12 | -9.5 | -9.3 | -17 | -158 | 196 | -155 | 4.4 | -12 | 8.8 | -2.2 | -37 | 15 | 7.6 | -11 | -25 | |
| -1.5 | -1.7 | -2.2 | -2.6 | -4.7 | -4.7 | -5.8 | -9.1 | -9.2 | -17 | -12 | -12 | -9.9 | -9.7 | -17 | -14 | -22 | -11 | -18 | -20 | -25 | -24 | -22 | -24 | -33 | -31 | -110 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.